Healthcare Analysts, along with Drs. Frank Tarazi and Friedland discuss the upcoming Clinical Trials in Alzheimer’s Disease (CTAD) Meeting and Eisai and Biogen’s Lecanemab in the first of two Analyst/Industry conference calls to be held on December 1.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ESALY:
- Mizuho says Biogen not mentioned in 90 minute lecanemab presentation
- Biogen price target raised to $350 from $325 at Jefferies
- Biogen and Eisai’s Alzheimer’s Drug May Pose Serious Risks, Say Researchers
- Eisai and Biogen present full results for Lecanemab phase 3 study in AD
- Prothena data from AD/PD abstract ‘promising,’ says Jefferies